Kymera Therapeutics, Inc. (KYMR)

Several events impacted Kymera Therapeutics' stock in the past six months. Fourth Quarter and Full Year 2025 Financial Results were reported on February 26, 2026, and First Quarter 2026 Financial Results were announced on April 30, 2026, both providing pipeline and partnership updates. Positive results from the KT-621 Phase 1b Atopic Dermatitis Trial were presented at the AAD Annual Meeting in March 2026. The FDA granted Fast Track designation to KT-621 for eosinophilic asthma in April 2026. Dosing began in the KT-579 Phase 1 trial in February 2026, with data expected in the second half of 2026. Gilead exercised its option on KT-200 in April 2026, triggering a $45 million milestone payment. Sanofi ended work on KT-474 but prioritized KT-485. Kymera's stock increased by 10.6% between the beginning of 2026 and May 9, 2026, and by 289.96% over the last 12 months.

As a clinical-stage biopharmaceutical company, Kymera Therapeutics' products are in clinical trials and not yet commercialized. There is no indication of demand seasonality for its products or services at this time. Demand for future therapies will likely be driven by disease prevalence and treatment efficacy rather than seasonal patterns.

Kymera Therapeutics is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing small-molecule therapies using the body's protein homeostasis pathways. Their Pegasus™ platform identifies and eliminates disease-causing proteins across various therapeutic areas. Key product candidates include KT-621 (STAT6 degrader) in Phase 2b trials for atopic dermatitis and asthma, KT-579 (IRF5 degrader) in Phase 1 trials for autoimmune diseases, KT-485/SAR447971 (IRAK4 program) in Phase II trials for immuno-inflammatory diseases in partnership with Sanofi S.A., and a CDK2 molecular glue degrader program for oncology in collaboration with Gilead Sciences.

Kymera Therapeutics is headquartered in Watertown, Massachusetts, and incorporated in Delaware. While based in the U.S., its clinical trials are global, and it has strategic alliances with international pharmaceutical companies like Sanofi S.A. and Gilead Sciences, indicating an international reach.

Kymera Therapeutics has maintained a generally positive perception within the financial community, with a consensus rating of "Moderate Buy" from analysts. The company has addressed fraudulent job recruitment postings, advising that legitimate communications will only come from a @kymeratx.com email address.

Kymera Therapeutics has a mixed ownership structure with significant institutional and insider holdings. Major institutional owners include Fmr Llc, Baker Bros. Advisors Lp, and Vanguard Group Inc. Insiders hold approximately 16.01% of the company's stock, with Felix Baker being the largest individual shareholder.